Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 115 for your search:
Cancer Type:
Lymphoma, non-Hodgkin lymphoma, child
Stage/Subtype of Cancer:
recurrent childhood non-Hodgkin lymphoma
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
16 to 65
Sponsor:
Other
Protocol IDs:
MCC-14178
, NCT00361140
2.
Phase II/III Study of Standard and Novel Conditioning Therapy Followed By Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia or Hematologic Malignancy
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
4 to 70
Sponsor:
Other
Protocol IDs:
RPCI-RP-9815
, NCI-V99-1527, NCT00003816, RP 98-15
3.
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
12 to 55
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
GC P#02.01.001
, NCT00469729
4.
Phase II/III Study of Disease-Specific High-Dose Conditioning Regimens Followed by Autologous Stem Cell Transplantation (Single or Tandem) in Patients With Hematologic Malignancies or Solid Tumors
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
4 and over
Sponsor:
NCI
Protocol IDs:
RPCI-I-72806
, I 72806, NCT00536601
5.
Phase III Randomized Study of Nonmyeloablative Conditioning Comprising Low-Dose Total Body Irradiation With Versus Without Fludarabine Followed By HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies at Low or Moderate Risk For Graft Rejection
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 75
Sponsor:
NCI
Protocol IDs:
FHCRC-1813.00
, 5666, NCT00075478
6.
Phase I/II Study of Epstein Barr Virus Specific Cytotoxic T Lymphocytes from a Normal HLA-Compatible Donor in the Treatment of Patients With Epstein Barr Virus Associated Lymphomas and Other Lymphoproliferative Diseases
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
MSKCC-95024
, NCI-V95-0685, NCT00002663
7.
Phase I/II Study of Autologous Peripheral Blood Stem Cell Transplantation Followed by Nonmyeloablative Allogeneic PBSC Transplantation in Patients With Refractory or Relapsed Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
65 and under
Sponsor:
NCI
Protocol IDs:
FHCRC-1409.00
, 4903, NCI-G00-1776, NCT00005803
8.
Phase I/II Pilot Study of Non-Myeloablative Chemotherapy Followed By Allogeneic Stem Cell Transplantation in Pediatric Patients With Hematopoietic Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
4 to 21
Sponsor:
NCI
Protocol IDs:
NCI-01-C-0125F
, NCT00020592
9.
Stem Cell Transplant for Hematologic Diseases and Renal Cell Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
70 and under
Sponsor:
Other
Protocol IDs:
H8713
, NCT00058825
10.
Allogeneic Transplantation From Related Haploidentical Donors in Older Patients With Indolent Hematologic Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Older patients
Sponsor:
NCI, Other
Protocol IDs:
BMT124
, 75117, BMT124, NCT00185692, NCT00185692
11.
Phase I/II Pilot Study of Ifosfamide, Carboplatin, Etoposide, and Monoclonal Antibody SGN-30 in Pediatric Patients With CD30-Positive Recurrent Anaplastic Large Cell Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 to 21
Sponsor:
NCI
Protocol IDs:
COG-ANHL06P1
, ANHL06P1, NCT00354107
12.
Phase I/II Study of Clofarabine in Patients With Relapsed or Refractory T-Cell or Natural Killer-Cell Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
2 and over
Sponsor:
NCI
Protocol IDs:
MSKCC-06065
, NCT00416351
13.
Phase I/II Study of Conditioning Regimen Comprising Clofarabine, Melphalan, and Alemtuzumab Followed By Allogeneic Stem Cell Transplantation in Patients With Advanced Hematologic Malignancies or Other Diseases
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
75 and under
Sponsor:
NCI
Protocol IDs:
UCCRC-14341B
, 14341B, UCCRC-05-155, NCT00572546
14.
Phase I/II Study of Reduced-Intensity Preparative Regimen Comprising Fludarabine, Busulfan, and Alemtuzumab Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies or Other Diseases
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
70 and under
Sponsor:
Other
Protocol IDs:
BCM-H-19386
, BCM-FAB, H 19386, NCT00625144
15.
Phase I/II Pilot Study of a Nonmyeloablative Conditioning Regimen Comprising Anti-CD45 Monoclonal Antibody, Alemtuzumab, Fludarabine Phosphate , and Low-Dose Total-Body Irradiation Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients With High-Risk Hematological Diseases
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Under 100
Sponsor:
Other
Protocol IDs:
BCM-H-12472
, H 12472, BCM-ACHE, NCT00056966
16.
Phase I/II Pilot Study of WT-1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion in Patients With WT1-Expressing Progressive or Relapsed Hematologic Malignancies After Prior Allogeneic Stem Cell Transplantation
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 to 75
Sponsor:
NCI
Protocol IDs:
NCI-08-C-0051
, 08-C-0051, NCI-P06049, NCT00608166
17.
Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
0 to 55
Sponsor:
Other
Protocol IDs:
8717
, NCT00673114
18.
A Multi-Center Phase I Study of AP23573 in Pediatric Patients With Advanced Solid Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 to 17
Sponsor:
Other
Protocol IDs:
SUN08-01
, NCT00704054
19.
Phase I/II Study of Dasatinib in Combination With Ifosfamide, Carboplatin, and Etoposide Phosphate in Young Patients With Metastatic or Recurrent Malignant Solid Tumors
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 to 25
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
CHNMC-07053
, 07053, CA180 121, NCT00788125
20.
Phase I/II Prospective Study of Nonmyeloablative Related Allogeneic HLA-Haploidentical Bone Marrow Transplantation Followed By Single Prophylactic Donor Lymphocyte Infusion of NK Cells in Patients With Hematological Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
NCI
Protocol IDs:
FHCRC-2230.00
, 2230.00, IR-6771, NCT00789776
21.
Double Cord Blood Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
30 and under
Sponsor:
Other
Protocol IDs:
CHNY-06-533
, IRB AAAC3457, NCT00801931
22.
Autologous and Allogeneic Transplant for Relapsed Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
30 and under
Sponsor:
Other
Protocol IDs:
CHNY-01-501
, AAAA5185, NCT00802113
23.
TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 and over
Sponsor:
Other
Protocol IDs:
6895
, 2323.00, NCT00867139
24.
Phase II Study of Interferon alfa in Patients With Grade I, II, or III Lymphomatoid Granulomatosis and of Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab in Patients With Grade III Lymphomatoid Granulomatosis
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
12 and over
Sponsor:
NCI
Protocol IDs:
NCI-94-C-0074
, NCI-MB-325, NCT00018993
25.
Phase II Study of Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematologic Disease or Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
8 to 80
Sponsor:
NHLBI
Protocol IDs:
NHLBI-99-H-0050
, NCT00003838
Select All on Page
1
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
